 |
|
|
| |
No Significant Effect of the HCV Protease Inhibitor Telaprevir on Pharmacokinetics and Pharmacodynamics of Buprenorphine in HCV-negative Volunteers
|
| |
| |
Reported by Jules Levin
HEP DART 2011, Koloa, Hawaii, USA, December 4-8, 2011
X Luo1, J Trevejo1, R van Heeswijk2, V Garg*1
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 2Tibotec BVBA, Beerse, Belgium
|
| |
|
|
|
|
|
